3D Global Biotech Inc. (6808.TWO)
- Previous Close
61.40 - Open
61.40 - Bid 60.10 x --
- Ask 60.50 x --
- Day's Range
60.00 - 61.40 - 52 Week Range
33.70 - 73.50 - Volume
186,213 - Avg. Volume
472,180 - Market Cap (intraday)
4.678B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
46.23 - EPS (TTM)
1.30 - Earnings Date --
- Forward Dividend & Yield 0.53 (0.86%)
- Ex-Dividend Date Jul 7, 2025
- 1y Target Est
--
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research. It offers artificial bone substitute, skull fixation system, biological dressings, bio inks, and bioprinting equipment, as well as orthopedic, tooth and jaw, and skull reconstruction products, and scalp care products. It serves medical centers, research institutions, and companies and distributors to establish an interdisciplinary alliance encompassing industry, government, academia, research, and medicine. The company was founded in 2014 and is based in New Taipei City, China.
www.3dglobalbiotech.com.twRecent News: 6808.TWO
View MorePerformance Overview: 6808.TWO
Trailing total returns as of 6/16/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6808.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6808.TWO
View MoreValuation Measures
Market Cap
4.78B
Enterprise Value
4.16B
Trailing P/E
47.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.36
Price/Book (mrq)
5.28
Enterprise Value/Revenue
15.66
Enterprise Value/EBITDA
35.25
Financial Highlights
Profitability and Income Statement
Profit Margin
34.51%
Return on Assets (ttm)
8.12%
Return on Equity (ttm)
15.31%
Revenue (ttm)
265.69M
Net Income Avi to Common (ttm)
91.7M
Diluted EPS (ttm)
1.30
Balance Sheet and Cash Flow
Total Cash (mrq)
703.86M
Total Debt/Equity (mrq)
9.37%
Levered Free Cash Flow (ttm)
-24.67M